Moderna, Inc. (MRNA) Options Risk Score

Run a full MRNA options risk analysis

See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.

Is it risky to sell options on Moderna, Inc. (MRNA) right now?

For a 4-week expiry, Moderna, Inc. (MRNA) carries an options catalyst-risk score of 100 out of 100 (HIGH). That score is driven by an upcoming earnings report, 9 recent news items, 3 active legal filings, 3 recent SEC events and 40 clinical-trial catalysts falling inside the 4-week window. On TickerRisk's scale 70 and above is HIGH, so a known event is scheduled inside this window — selling premium on MRNA here is a bet on that event rather than on time decay. The score measures scheduled event exposure, not which way the stock will move.

MRNA shows an IV Rank of 59, putting implied volatility in the middle of its one-year range — options are moderately priced, with a current implied volatility of about 80%. Read IV Rank alongside the catalyst score: it says how expensive MRNA options are, while the score says whether that price is justified by a scheduled event.

The 2026-11-05 earnings report sits inside a standard monthly expiry for MRNA, so implied volatility should stay bid into the date and drop sharply once it passes.

Moderna, Inc. (MRNA) current implied volatility and IV Rank

MRNA is trading at an IV Rank of 59 with implied volatility around 80%, alongside a TickerRisk options-risk score of 100/100. MRNA's options are priced near the middle of their own yearly range — unremarkable volatility, so the trade has to stand on its own thesis rather than on rich or cheap premium.

For what this number does and does not tell you about MRNA's options, see IV Rank explained.

Moderna, Inc. (MRNA) next earnings date — 2026-11-05

Moderna, Inc. (MRNA) reports earnings on 2026-11-05 — about 59 days away, which falls inside a typical options expiry window. MRNA's IV Rank is currently 59. Earnings are the single biggest scheduled catalyst for an overnight gap: implied volatility usually runs up into the report and collapses immediately after (the IV crush). Selling premium into the event captures that crush but exposes you to the gap; buying premium needs a move large enough to beat the elevated IV you paid.

TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer